Biocon Limited, a global biopharmaceutical leader, has announced the launch of its GLP-1 peptide, Liraglutide, in the United Kingdom (U.K.) for diabetes and chronic weight management. The drug will be marketed under the brand names Liraglutide Biocon for diabetes (gVictoza®) and Biolide for obesity (gSaxenda®).
This milestone follows approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., making Biocon the first generics company to obtain approval for gLiraglutide in a major regulated market.
Siddharth Mittal, CEO & MD of Biocon Limited, stated, “The launch of our gLiraglutide in the U.K. is a significant step towards making affordable diabetes and obesity treatments more accessible. Our focus remains on expanding into other European markets, the U.S., and select MoW geographies, while strengthening our GLP-1 pipeline.”
With GLP-1 therapies driving future growth, Biocon is reinforcing its leadership in innovative biopharmaceutical solutions. The company’s strong scientific and manufacturing expertise ensures high-quality, cost-effective treatments for patients worldwide.
